Sirpa Leppa

Professor of Oncology, lymphoma doctor, chair of the NLG & NLG LBCL WG

[Sirpa Leppa @LeppaSM]

Happy to share our study on distinct cancer-associated fibroblasts (CAFs), their spatial architecture, and impact on survival in #Hodgkin #lymphoma just released in @Hemasphere_EHA at https://t.co/13QyhGj3VM

[Sirpa Leppa @LeppaSM]

@ProfChrisPFox Thanks 🙏, and yes, definitely 👍

[Sirpa Leppa @LeppaSM]

We demonstrate promising survival for high-risk LBCL patients, except for those with TP53 aberrations, high ctDNA levels, and/or EOT ctDNA (MRD) positivity. We also find that ctDNA negativity at the EOT indicates cure and effectively addresses false residual PET positivity.

[Sirpa Leppa @LeppaSM]

Happy to share the results of the Nordic biomarker-adapted trial in patients with high-risk LBCL (NLG-LBC-06) just released online in @Hemasphere_EHA at
https://t.co/Ujq3cKCYuM
We learned that prospective stratification according to biological risk factors is feasible.

[Daniel Molin @Dr_Daniel_Molin]

Here we introduce a simple 3-point frailty score for older Hodgkin patients to inform clinical decisions and prospective trials for older patients. Happy to participate in this Norwegian initiative!

Early View | Haematologica https://t.co/oe6eSkuzoo

[Sirpa Leppa @LeppaSM]

Excellent educational overview of the management of DLBCL as well as self-assessment case by Raúl Cordoba at the @EHA_Hematology - HKSH Hematology Tutorial in Lymphoid Malignancies 2025.
”The first bullet is the best bullet”

[Raul Cordoba, MD, PhD @DrRaulCordoba]

@EHA_Hematology is joining the Hong Kong Society of Hematology (HKSH) to organize the #Hematology Tutorial on Lymphoid Malignancies.

📆 5-6 April 2025
📍 Hong Kong 🇭🇰

#lymsm

[Cancer Cell @Cancer_Cell]

Online Now: Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics https://t.co/Ou2Wf8wBir

[European Hematology Association @EHA_Hematology]

Applications for #TRTH2026 are now open!
Are you an early-career researcher in translational hematology? The EHA-ASH TRTH program provides a unique opportunity to enhance your research skills with guidance from leading international experts.

🔹 Applications open today, March 15!
🔹 Deadline: June 26, 2025, at 11:59 PM ET

Don’t miss this chance to advance your career in hematology research. Apply now!
Learn more: https://t.co/diy1y1aUFg
Apply now: https://t.co/obTrl2yGwi

#HematologyResearch #CareerDevelopment #TRTH #TRTH2026

[European Hematology Association @EHA_Hematology]

We've kicked-off our first research training program for 2025. This week we've gathered a cohort of 20 young hematologists to undertake Clinical Research Training in Hematology in Milan. Over four days, they will hear from the brightest minds, discussing key topics shaping the future of clinical trials. 

Novel Designs for Early Phase Trials – Christina Yap shared innovative approaches to designing early-phase trials that could transform clinical research. Patient Involvement in Trial Design & Research Grant Applications – Jan Geissler emphasized the importance of engaging patients in trial designs and the grant application process, ensuring research is both impactful and patient-centered. These discussions sparked valuable ideas on collaboration, innovation, and patient advocacy. 

🚨 CRTH 2026 cohort applications open in June 2025! Are you eligible for the CRTH Training Program? Find out here: https://t.co/dAoD83D8hu

#CRTHWorkshop #ClinicalResearch #Innovation #PatientInvolvement #EarlyPhaseTrials #YoungEHA

[Sirpa Leppa @LeppaSM]

👍I fully agree. #EHACRTH is an excellent opportunity to learn to conduct clinical trials in hematology, network internationally and get new friends.

[Kate Cwynarski @CwynKate]

#EHACRTH a privilege to be involved & many colleagues to celebrate & learn from
@EHA_Hematology

@DrRaulCordoba @_DrCP @LeppaSM #AmyKirkwood @jangeissler
@kate_orf @ABarrettHaem & many others

Further work to be done in June & September

Highly recommended for all involved

[Sirpa Leppa @LeppaSM]

Syöpätautien erikoislääkäri ja TYKSn tulosryhmäjohtaja Sirkku Jyrkkiölle myönnettiin juuri lääkäripäivien avajaisissa Max Oker-Blom palkinto ansiokkaasta lääkärijohtamisesta. Oikein meni. Lämpimät onnittelut Sirkku!
#lääkäripäivät @DuodecimFi @Laakariliitto

[Sirpa Leppa @LeppaSM]

@AnnaSureda5 @Haematologica Thanks 😊! Happy New Year to you as well Anna 🌌!

[Sirpa Leppa @LeppaSM]

Happy to share our work just published online in https://t.co/GktyXa36lx
@Haematologica . We dissected the composition and spatial interactions of the TME in GCB, ABC and testicular DLBCLs and found biologically and clinically relevant differences between the subtypes.

[Sirpa Leppa @LeppaSM]

@miheger @Haematologica Thank you Michel 😊!

[Sirpa Leppa @LeppaSM]

@LiaPalomba @Haematologica Thank you Lia 😊!

[thisisFINLAND @thisisFINLAND]

Tonight, Santa will embark on his journey from Lapland to around the world as a true ambassador of goodwill, bringing Christmas cheer to millions of homes.

Happy Holidays! ❤️🎅🏻

[Sirpa Leppa @LeppaSM]

@DrRaulCordoba @Haematologica Thanks🙏😊

[Sirpa Leppa @LeppaSM]

For example, ABC DLBCL has a more cytotoxic TME, and a predominance of M2-like TAMs, whereas T helper cells and Tregs characterize the TME in the GCB DLBCL. The TME in T-DLBCL is similar to the TME of ABC DLBCL.
M Autio, @LeivonenSuvi @oscarbruck @MarjukkaPollari et al.

[Sirpa Leppa @LeppaSM]

@Sampsa_H @Syopasaatio Warm congratulations Sampsa 🎉